Enhanced sensitivity to topoisomerase inhibitors in synchronous CHO cells pre-treated with 5-azacytidine

Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis

Volumn 421, Issue 1, 1998, Pages 109-116

  López Baena, Manuela ^a   Mateos, Santiago ^a   Piñero, Joaquín ^a   Ortiz, Trinidad ^a   Cortés, Felipe ^a,b  

^a UNIVERSITY OF SEVILLE   (Spain)

^b Facultad de Biología   (Spain)

Author keywords

5 Azacytidine; DNA damage; Topoisomerase inhibitor

Indexed keywords

AMSACRINE; AZACITIDINE; CAMPTOTHECIN; DNA TOPOISOMERASE INHIBITOR;

ANIMAL TISSUE; ARTICLE; CELL CYCLE S PHASE; CELL SYNCHRONIZATION; CHO CELL; CHROMOSOME ABERRATION; CHROMOSOME REPLICATION; CONTROLLED STUDY; CYTOGENETICS; DNA METHYLATION; DRUG POTENTIATION; DRUG SENSITIVITY; NONHUMAN; PRIORITY JOURNAL;

AMSACRINE; ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; AZACITIDINE; CAMPTOTHECIN; CHO CELLS; CHROMOSOME ABERRATIONS; CRICETINAE; DNA METHYLATION; DNA TOPOISOMERASES, TYPE I; DNA TOPOISOMERASES, TYPE II; DRUG INTERACTIONS; ENZYME INHIBITORS; S PHASE;

CRICETINAE; CRICETULUS GRISEUS;

EID: 0032511823     PISSN: 00275107     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0027-5107(98)00162-6     Document Type: Article

References (43)

1. [1] D. Von Hoff, M. Slavik, F. Muggia, 5-Azacytidine: a new anticancer drug with efectiveness in acute myelogenous leukaemia, Annu. Int. Med. 85 (1976) 237-245.
2. [2] P.A. Jones, S.M. Taylor, Cellular differentiation, cytidine analogs and DNA methylation, Cell 20 (1980) 85-93.
3. [3] I. Keshet, J. Lieman-Hurwitz, H. Cedar, DNA methylation affects the formation of active chromatin, Cell 44 (1986) 535-543.
4. [4] A. Bird, The essentials of DNA methylation, Cell 70 (1992) 5-8.
5. [5] D.A. Shafer, J.H. Priest, Reversal of DNA methylation with 5-azacytidine alters chromosome replication patterns in human lymphocytes and fibroblast cultures, Am. J. Hum. Genet. 36 (1984) 534-545.
6. [6] E. Jablonka, R. Goitein, M. Marcus, H.C. Cedar, DNA hypomethylation causes an increase in Dnase-I sensitivity and an advance in the time of replication of the entire inactive X chromosome, Chromosoma 93 (1985) 152-156.
7. [7] E. Jablonka, R. Goitein, K. Speclinas, H. Cedar, M. Marcus, 5-aza-C-induced changes in the time of replication of the X chromosomes of Microtus agrestis are followed by non-random reversion to a late pattern of replication, Chromosoma 95 (1987) 81-88.
8. [8] E. Li, T. Bestor, R. Jaenisch, Targeted mutation of the DNA methyltransferase gene results in embryonic lethality, Cell 69 (1992) 915-926.
9. [9] H. Leonhardt, A. Page, H. Weier, T. Bestor, A targeting sequence directs DNA methyltransferase to sites of DNA replication in mammalian nuclei, Cell 71 (1992) 865-873.
10. [10] S. Rainier, L.A. Johson, C.J. Dobry, A.J. Ping, P.E. Grundy, A.P. Feinberg, Relaxation of imprinted genes in human cancer, Nature 362 (1993) 747-751.
11. [11] J.C. Wang, DNA topoisomerases, Annu. Rev. Biochem. 54 (1985) 665-697.
12. [12] P. D'Arpa, C. Beardmore, L.F. Liu, Involvement of nucleic acid synthesis in cell killing mechanism of topoisomerase poisons, Cancer Res. 51 (1990) 6919-6924.
13. [13] L.H.C. Liu, DNA topoisomerase poisons as antitumour drugs, Annu. Rev. Biochem. 58 (1989) 351-375.
14. [14] P.J. Smith, DNA topoisomerase dysfunction: a new goal for antitumor chemotherapy, BioEssays 12 (1990) 167-172.
15. [15] H. Zhang, P. D'Arpa, L.F. Liu, A model for tumor cell killing by topoisomerase poisons, Cancer Cells 2 (1990) 23-27.
16. [16] F. Cortés, J. Piñero, F. Paliti, Cytogenetic effects of inhibition of topoisomerase I or II activities in the CHO mutant EM9 and its parental line AA8, Mutat. Res. 288 (1993) 281-289.
17. [17] Y.-H. Hsiang, M.G. Lihon, L.F. Liu, Arrest of replication forks by drugs-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin, Cancer Res. 49 (1989) 5077-5082.
18. [18] C. Holm, J.M. Covey, D. Kerrigan, Y.C. Pommier, Differential requirement of DNA replication for the cytotoxicity of DNA topoisomerase I and II inhibitors in Chinese hamster DC3F cells, Cancer Res. 49 (1989) 6365-6368.
19. [19] F. Cortés, J. Piñero, T. Ortiz, Importance of replication fork progression for the induction of chromosome damage and SCE by inhibitors of DNA topoisomerases, Mutat. Res. 303 (1993) 71-76.
20. [20] H.G. Graztner, Monoclonal antibody to 5-bromo-and-5-iododeoxyuridine, a new reagent for detection of DNA replication, Science 218 (1982) 474-475.
21. [21] F. Leteurtre, G. Kohlhagen, R.F. Mark, A. Tanizawa, L.W. Kohn, I. Pommier, Effects of DNA methylation on topoisomerase I and II cleavage activities, J. Biol. Chem. 269 (1994) 7893-7900.
22. [22] L.A. Zwelling, S. Michaels, L.C. Erickson, R.S. Ungerleider, M. Nichols, K.W. Kohn, Protein-associated deoxyribonucleic acid strand breaks in LIZ 10 cells treated with the deoxy ribonucleic acid intercalating agents 4′-(9-accydinylamino)-methanesulfon-m-anisidide and adriamycin, Biochemistry 20 (1981) 6553-6563.
23. [23] L. Yanes, T.C. Rowe, E.M. Nelson, L.F. Liu, In vivo mapping of DNA topoisomerase II-specific cleavage sites in SV40 chromatin, Cell 41 (1985) 127-132.
24. [24] J. Minford, Y. Pommier, J. Filipskis, K.W. Kohn, D. Kerrigan, M. Mattrn, S. Michaels, R. Schwartz, L.A. Zwelling, Isolation of intercalator dependent protein-linked DNA strand cleavage activity from cell nuclei and identification as topoisomerase II, Biochemistry 25 (1986) 9-16.
25. [25] J.L. Nitiss, J.C. Wang, DNA topoisomerase can be studied in yeast, Proc. Natl. Acad. Sci. U.S.A. 85 (1988) 7501-7505.
26. [26] Y.-H. Man, M.J.F. Dustin, Y. Pommier, L.F. Povirk, Small deletion and insertion mutations induced by the topoisomerase II inhibitor teniposide in CHO cells and comparison with sites of drugs-stimulated DNA cleavage in vitro, J. Mol. Biol. 229 (1993) 52-66.
27. [27] M. Charron, R. Hancock, Chromosome recombination and defective genome segregation induced in Chinese hamster cells by the topoisomerase II inhibitor VH-26, Chromosoma 100 (1991) 97-102.
28. [28] H.C. Anderson, B.A. Kihlman, The production of chromosomal alterations in human lymphocytes by drugs known to interfere with the activity of DNA topoisomerase II: I. m-AMSA, Carcinogenesis 10 (1989) 123-130.
29. [29] R.D. Snyder, P.J. Lackmann, Differential effects of 5-azacytidine and 5-azadeoxycytidine on cytotoxicity, DNA-strand breaking and repair of X-ray-induced DNA damage in Hela cells, Mutat. Res. 226 (1989) 185-190.
30. [30] I.D. Hickson, S.L. Davies, S.M. Davies, C.N. Robson, DNA repair in radiation sensitive mutants of mammalian cells: possible involvement of DNA topoisomerases, Int. J. Radiat. Biol. 58 (1990) 561-568.
31. [31] W.C. Dewey, S.C. Furman, H.H. Miller, Comparison of lethality and chromosome damage induced by X-rays in synchronised chinese hamster cells in vitro, Radiat. Res. 43 (1970) 561-581.
32. [32] G.P. Joshi, W.J. Nelson, S.H. Revel, C.A. Shaw, X-ray induced chromosome damage in live mammalian cells and impaired measurements of its effects on their colony forming ability, Int. J. Radiat. Biol. 41 (1982) 161-181.
33. [33] M.K. Dansk, J.C. Yalowic, W.T. Beck, Atypical multiple drug resistance in a human leukemic cell line selected for resistance to teniposide (VM-26), Cancer Res. 47 (1987) 1297-1301.
34. [34] L.A. Zwelling, M. Hinds, D. Chan, J. Mayes, K.L. Sie, E. Parker, A. Silberman, A. Radcliffe, M. Beran, M. Blick, Characterization of an amsacrine-resistant line of human leukemic cells. Evidence for a drug-resistant form of topoisomerase II, J. Biol. Chem. 264 (1989) 16411-16420.
35. [35] D.J. Fernandes, M.K. Dansk, W.Y. Beck, Decreased nuclear matrix DNA topoisomerase II (topo II) in VM-26 resistant human leukaemia cells, Proc. Am. Assoc. Cancer Res. 30 (1989) 502.
36. [36] B.C. Giovanella, J.S. Stehlin, M.E. Wall, M.C. Wani, A.W. Nicholas, L.F. Liu, R. Silber, M. Potmesil, DNA topoisomerase I target chemotherapy of human colon cancer xenographs, Science 246 (1989) 1046-1048.
37. [37] T. Andoh, K. Ishii, Y. Suzuki, Y. Ikegami, Y. Kusunoki, Y. Takemoto, K. Okada, Characterization of a mammalian mutant with a camptothecin-resistant DNA-topoisomerase I, Proc. Natl. Acad. Sci. U.S.A. 84 (1987) 5565-5569.
38. [38] K.B. Tan, M.R. Mattern, W.K. Eng, F.L. Eng, McCabe, R.K. Johnson, Nonreproductive rearrangement of DNA topoisomerase I and II genes: correlation with resistance to topoisomerase inhibitors, J. Natl. Cancer Inst. 81 (1989) 1732-1735.
39. [39] G. Taudou, G. Mirambean, C. Lavenot, A. Garabedian, J. Vermeersch, M. Duguet, DNA topoisomerase activities in concanavalin A-stimulated lymphocytes, FEBS Lett. 176 (1984) 431-435.
40. [40] M.M. Heck, W.C. Earnshaw, A specific marker for cell proliferation, J. Cell Biol. 103 (1986) 2569-2581.
41. [41] Y.H. Hsiang, H.Y. Wu, L.F. Liu, Proliferation-dependent regulation of DNA topoisomerase II in cultured human cells, Cancer Res. 48 (1988) 3230-3235.
42. [42] D.M. Sullivan, B.S. Glisson, P.K. Hodges, S. Smallwood-Kentro, W.E. Ross, Proliferation dependence of topoisomerase II mediated drug action, Biochemistry 25 (1986) 2248-2256.
43. [43] M.D. Crespi, A.G. Mladovan, A. Baldi, Increment of DNA topoisomerases in chemically and virally transformed cells, Exp. Cell. Res. 175 (1988) 206-215.